Humanize Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.90 M
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 3.71%
- Profit Growth 71.70%
- Ebitda 149.06%
- Net Worth -19.24%
- Total Assets -4.10%
About Humanize Pharmaceuticals
Humanize Pharmaceuticals Private Limited (HPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 March 2016 (Eight years and 11 months 15 days old ). Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.90 M, as per Ministry of Corporate Affairs (MCA) records.
Ijaj Khalif, Vishwanath Hanji, Pradeep Sankpal, and Three other members serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999PN2016PTC158796
- Company No.
158796
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Mar 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Humanize Pharmaceuticals?
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ijaj Khalif  | Director | 11-Mar-2016 | Current |
| Vishwanath Hanji | Director | 11-Mar-2016 | Current |
| Pradeep Sankpal | Director | 11-Mar-2016 | Current |
| Prithviraj Desai | Director | 11-Mar-2016 | Current |
| Swati Bandi | Director | 11-Mar-2016 | Current |
| Ajit Desai | Director | 11-Mar-2016 | Current |
Financial Performance of Humanize Pharmaceuticals.
Humanize Pharmaceuticals Private Limited, for the financial year ended 2021, experienced modest growth in revenue, with a 3.71% increase. The company also saw a substantial improvement in profitability, with a 71.7% increase in profit. The company's net worth observed a substantial decline by a decrease of 19.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Humanize Pharmaceuticals?
In 2021, Humanize Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Gadhinglaj Pharma LlpVishwanath Hanji and Pradeep Sankpal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Humanize Pharmaceuticals?
Unlock and access historical data on people associated with Humanize Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Humanize Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Humanize Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
